In July 2024, European regulators rejected Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. By November, they had changed their minds. Now, the…
Eisai and Biogen’s Alzheimer’s drug Leqembi (generic name lecanemab) was the first fully-FDA approved disease-modifying treatment for early-stage Alzheimer’s disease in United States history,…
ApoE4, a genetic variation sometimes referred to as the “Alzheimer’s gene,” is one of the most influential genetic risk factors for developing Alzheimer’s disease….
When Eisai announced in a press release this week that they’d secured FDA approval for an Alzheimer’s drug dosage change, it seemed like a…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
This article is part of the Journey to Diagnosis series, produced by Being Patient with support provided by Eli Lilly. In the newest definition…
Since Leqembi was approved in the U.S. in the summer of 2023, controversy has roiled among clinicians over whether the Alzheimer’s anti-amyloid drug’s risks…
In just a single year of studying a rare genetic mutation in a single family in the Arctic reaches of remote northern Sweden, a…
On August 22nd, the UK’s drug regulation agency — UK Medicines and Healthcare products Regulatory Agency — approved Eisai and Biogen’s anti-amyloid drug Leqembi…
Medicare covers the cost of the anti-amyloid Alzheimer’s drug Leqembi, but many people with Alzheimer’s are under the age of 65 and don’t yet…
On July 25th, European regulators said no to Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. The European Medicines Agency (Europe’s version…
Diagnosed with Alzheimer’s and one of the relative few who has gotten a prescription for the new, disease-modifying anti-amyloid drug Leqembi? If you live…
Alzheimer’s disease affects millions of people worldwide, and as the world’s population ages, that number is going up. But, the exact cause of Alzheimer’s…
Neurologists and Alzheimer’s research experts explain the side effect known as ARIA — or brain bleeds — associated with the use of anti-amyloid monoclonal antibody…
On July 6, 2023, the U.S. Food and Drug Administration fully approved the Alzheimer’s drug Leqembi (generic name lecanemab), a monoclonal antibody drug for…